CommentTreating giant-cell arteritis: is IL-6 the cytokine to target?
References (11)
- et al.
Pathogenesis of giant cell arteritis: More than just an inflammatory condition?
Autoimmun Rev
(2010) Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
Trends Immunol
(2012)- et al.
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Lancet
(2016) - et al.
Giant-cell arteritis and polymyalgia rheumatica
N Engl J Med
(2014) - et al.
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis
Arthritis Rheum
(2012)
There are more references available in the full text version of this article.
Cited by (8)
Therapeutic strategy in giant cell arteritis
2017, Revue du Rhumatisme MonographiesClinical presentation of ischemic optic neuropathies
2023, Expert Review of OphthalmologyGiant Cell Arteritis: Practical Pearls and Updates
2018, Current Pain and Headache ReportsSirukumab: a promising therapy for rheumatoid arthritis
2017, Expert Opinion on Biological TherapyVaricella zoster virus-infected cerebrovascular cells produce a proinflammatory environment
2017, Neurology: Neuroimmunology and NeuroInflammation
© 2016 Elsevier Ltd. All rights reserved.